Technology Commercialization Group signs agreement to represent Optimapharm in US market

Technology Commercialization Group, LLC (TCG), a healthcare consultancy based in Research Triangle Park, North Carolina has signed an agreement to represent Optimapharm d.o.o., as it enters the US market. Optimapharm is a leading Southeastern European (SEE) based clinical research organization (CRO). The Company is headquartered in Zagreb, Croatia with additional offices in Belgrade, Serbia covering unique SEE clinical centers. Using their highly trained managers, Optimapharm has conducted more than 75 clinical studies since its inception in 2006 and serves six (6) SEE countries (Croatia, Slovenia, Serbia, Bosnia and Herzegovina, Montenegro and FYR Macedonia) as well as 22 other European countries through strategic partnerships.

“We are the leading CRO in our region having extensive experience in Oncology, Psychiatry/Central Nervous System, Cardiovascular and Metabolic Diseases. Our highly trained investigators in six countries can deliver a naïve treatment population of more than 25 million patients to US clinical researchers.”

"The agreement between Optimapharm and TCG enables us to offer high quality CRO services to US clients in a European Region not heavily burdened with competing clinical studies," said Gordana Greguric Cicak, MD, Chief Executive Officer of Optimapharm. "We are the leading CRO in our region having extensive experience in Oncology, Psychiatry/Central Nervous System, Cardiovascular and Metabolic Diseases. Our highly trained investigators in six countries can deliver a naïve treatment population of more than 25 million patients to US clinical researchers."

"We are very pleased to represent Optimapharm in the United States," said John Icardi, TCG Partner who will head the project. Croatia and Slovenia, being European Union members, gives US clients the confidence to contract with us, knowing we carefully operate to EMA and ICH/GCP standards. Our additional value however, is the limited number of clinical projects in the SEE Region and our unique ability to rapidly enroll qualified patients through highly motivated investigators. Optimapharm has trained many of those investigators."

Optimapharm will be attending several US healthcare conferences this fall to introduce its experience and capabilities, beginning with BioPharm America in Boston in September 2013.